NERCE/BEID is a network of research collaborations that fosters development of vaccines and therapies against infections caused by weapons of bioterrorism, and against emerging infectious disease.
National Screening Laboratory (NSRB)
The NSRB (formerly the NERCE Small Molecule Screening Core Laboratory) supports biodefense-related research directed towards the identification of small molecules that enhance our understanding of the basic biology of pathogens of biodefense or emerging infectious disease interest, and development of new therapeutic agents against these pathogens. The NSRB has funding to provide nationwide capability for small molecule screening, and the facility’s equipment, compound collections, and expertise are available to all U.S. investigators interested in conducting screens involving NIAID Priority Pathogens.
Supports diverse screening platforms
- assay types – whole cell/whole bacterial, protein-protein, protein-ligand
- assay readouts – plate reader and automated microscopy
Medicinal chemistry capability
Assay development capability
Full-time staff – screening, assay development, informatics, medicinal chemistry
Minimal cost to users
- no fees for Laboratory equipment or staff time
- Substantial portion of consumables cost provided by NERCE
Affiliated with:
- Institute for Chemistry and Chemical Biology, Longwood (ICCB-L)
http://iccb.med.harvard.edu/ - Laboratory for Drug Discovery in Neurodegeneration (LDDN)
http://www.hcnr.med.harvard.edu/programs/drugDisc.php
Principal Investigators : Stephen Lory, Ph.D. and John Clardy, Ph.D.
Contact
Su Chiang, Ph.D.
Assistant Director, Small Molecule Screening Core Laboratory
su_chiang@hms.harvard.edu
617-432-5237
FAX: 617-432-6424